Format

Send to

Choose Destination
Nat Med. 2018 Dec;24(12):1942. doi: 10.1038/s41591-018-0252-y.

Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma.

Author information

1
Department of Melanoma Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
2
Department of Breast Medical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
3
Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA.
4
Department of Head and Neck Surgery, MD Anderson Cancer Center, Houston, TX, USA.
5
Department of Immunology, MD Anderson Cancer Center, Houston, TX, USA.
6
Department of Biostatistics, MD Anderson Cancer Center, Houston, TX, USA.
7
Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
8
Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA.
9
Department of Pathology, MD Anderson Cancer Center, Houston, TX, USA.
10
Department of Genitourinary Cancers, MD Anderson Cancer Center, Houston, TX, USA.
11
Department of Translational and Molecular Pathology, MD Anderson Cancer Center, Houston, TX, USA.
12
Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.
13
Department of Genomic Medicine, MD Anderson Cancer Center, Houston, TX, USA. jwargo@mdanderson.org.

Abstract

In the version of this article originally published, there was an error in Fig. 1. In the neoadjuvant phase column, the n values for arms A and B were both reported to be 20. The n values for arms A and B were actually 12 and 11, respectively. Also, the URL underlying the accession code in the data availability section was incorrect. The URL was originally https://www.ebi.ac.uk/ega/studies/EGAS00001002698. It should have been https://www.ebi.ac.uk/ega/studies/EGAS00001003178. The errors have been corrected in the print, HTML and PDF versions of this article.

PMID:
30361511
DOI:
10.1038/s41591-018-0252-y

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center